ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2251

Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a  Prospective, Observational Registry

William G. Bensen1, Algis V Jovaisas2, J. Carter Thorne3, Philip Baer4, Majed M. Khraishi5, Sanjay Dixit6, Denis Choquette7, Michael Starr8, Isabelle Fortin9, Dalton E. Sholter10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, Francois Nantel13, Allen J. Lehman14, May Shawi15 and Susan M. Otawa14, 1Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Southlake Regional Health Centre, Newmarket, ON, Canada, 4Private Practice, Scarborough, ON, Canada, 5Nexus Clinical Research, St John's, NF, Canada, 6McMaster University, Hamilton, ON, Canada, 7Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 8Montreal General Hospital, Montreal, QC, Canada, 9Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 10Rheumatology Associates, Edmonton, AB, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, outcome measures and remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended Boolean definition and the Patient Activity Scale (PAS).

 

The aim of this analysis is to describe the agreement between these five indices in classifying remission as well as to assess their correlation in a routine clinical care setting.

 

Methods: BioTRAC is an ongoing, prospective Canadian registry of rheumatology patients initiating treatment with infliximab or golimumab. In this analysis, data from RA patients who were treated with infliximab between January 2002 and June 2011 and had available information in all indices were used. The definitions for remission were as follows: DAS28 <2.6; SDAI ≤ 3.3, CDAI ≤ 2.8; PAS ≤ 1.0. Factor analysis was used to assess the variability due to each of the indices while inter-item correlation was measured with the Pearson correlation coefficient.

 

Results: Seven hundred thirty four RA patients who had 3,035 complete assessments were included in the analysis. Non-remission was classified by all indices in 63.1% of the cases, while 36.9% achieved remission in one (13.1%), two (7.8%), three (1.9%), four (4.9%) and all five types (9.1%) of indices. Factor analysis showed that PAS accounted for 70.4% of the matrix variance, followed by DAS28-CRP (13.4%), SDAI (9.0%), CDAI (5.6%), and Boolean remission (1.6%), suggesting that PAS may reflect different aspects than the clinical indices. PAS remission revealed the lowest correlation with remission classified by the remaining indices (Table 1) and removal of any index, except PAS, would result in a lower overall Cronbach’s alpha.

 

Conclusion: The results of this analysis show that variability exists in the classification of remission by various disease activity indices. This variability was found to be predominantly due to the Patient Activity Scale, a patient-driven composite tool, suggesting that the patient perception of disease activity may differ from that captured by clinical outcome measures.

 

 

Table 1. Inter-Item Correlation Matrix of Disease Activity Indices

 

PAS

DAS28-CRP

SDAI

CDAI

Boolean

PAS

N/A

0.466

0.520

0.521

0.381

DAS28-CRP

0.466

N/A

0.653

0.626

0.661

SDAI

0.520

0.653

N/A

0.918

0.739

CDAI

0.521

0.626

0.918

N/A

0.718

Boolean

0.381

0.661

0.739

0.718

N/A

 


Disclosure:

W. G. Bensen,
None;

A. V. Jovaisas,
None;

J. C. Thorne,
None;

P. Baer,
None;

M. M. Khraishi,

Hoffman-La Roche Canada, Amgen and Pfizer Canada, and Abbott Canada.,

2;

S. Dixit,
None;

D. Choquette,
None;

M. Starr,
None;

I. Fortin,
None;

D. E. Sholter,
None;

E. Rampakakis,
None;

J. S. Sampalis,
None;

F. Nantel,
None;

A. J. Lehman,

Janssen Canada,

3;

M. Shawi,

Janssen Canada,

3;

S. M. Otawa,

Janssen Canada,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/variability-in-the-classification-of-remission-among-disease-activity-indices-and-their-correlation-an-analysis-from-a-prospective-observational-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology